Companies › Triple Hair
1 active drug program in 1 registered trial: 1 Phase 3; Immunology; next expected readout Dec 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| TH07 Fixed combination of 5-alpha reductase inhibitor (finasteride), alpha-adrenergic agonist ( | SRD5A2, PTGFR | Phase 3 | Androgenic Alopecia | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07435012 | TH07 | Phase 3 | Androgenic Alopecia | Immunology | Dec 2027 |
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair SpyGlass Pharma Glaukos YS Life Science Santen Pharmaceutical
Biopharma Plasma Psoriasis Research Institute of Guangzhou KalVista Pharmaceuticals Infant Bacterial Therapeutics Aresus Pharma
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.